Cannabis strain labels like "indica" and "sativa" don't reliably predict chemical content | Research

The takeaway

Analysis of commercial cannabis across six US states found distinct chemical profiles exist, but the strain names and indica/sativa labels commonly used to market products do not consistently predict their actual chemical composition.

Cannabis consumers choosing products, dispensary staff making recommendations, and regulators considering labeling requirements.

Commercial labels did not consistently match chemical profiles

What the researchers found

Distinct chemical phenotypes (chemotypes) were reliably present across commercial cannabis samples, but commercial labels (strain names, indica/sativa designations) did not consistently align with the observed chemical diversity, though certain labels showed biased associations with specific chemotypes.

Why it matters

Millions of consumers choose cannabis products based on strain names and indica/sativa labels that this study shows are unreliable predictors of what they are actually consuming, which has implications for both recreational and medical users.

The numbers in context

Samples analyzed across 6 US states. Distinct chemotypes identified. Commercial labels did not consistently align with chemical diversity. Some labels showed biased (but not reliable) associations with specific chemotypes.

How the study worked

Analyzed cannabinoid and terpene content of commercial cannabis samples across six US states. Compared observed phytochemical diversity to commercial labels. Identified chemotype clusters and assessed label-chemotype alignment.

What this study cannot tell us

The study examined available commercial products, which may not represent all cannabis varieties. Terpene and cannabinoid profiles can be affected by growing conditions, harvest timing, and storage, introducing variability beyond genetics.

How to read the evidence

Moderate: large-scale chemical analysis across multiple states, but commercial sample availability may introduce selection bias.

When this study was published

Published in 2022.

The bigger picture

As the cannabis industry matures, this research argues for moving toward chemotype-based labeling systems that tell consumers what is actually in their product, rather than relying on traditional nomenclature with little scientific basis.

Questions still open

Should regulators require chemotype-based labeling? Would consumers benefit from a standardized classification system? How much of the chemical variation is genetic versus environmental?

Common questions

Are indica and sativa labels meaningless?

Not entirely. Certain labels showed biased associations with specific chemotypes, but the relationship was not consistent or reliable enough to predict what a consumer would experience.

What are chemotypes?

Chemotypes are distinct chemical profiles based on the actual cannabinoid and terpene content of a cannabis sample, rather than its genetic lineage or marketing label.

What should consumers look for instead?

This research suggests that lab-tested cannabinoid and terpene profiles are more informative than strain names or indica/sativa labels for predicting the chemical content of a product.

Read the original research

The phytochemical diversity of commercial Cannabis in the United States.

PloS one, 17(5), e0267498

View on PubMed ↗Publisher’s paper ↗

Citation

Smith, Christiana J; Vergara, Daniela; Keegan, Brian; Jikomes, Nick. (2022). The phytochemical diversity of commercial Cannabis in the United States.. PloS one, 17(5), e0267498. https://doi.org/10.1371/journal.pone.0267498